PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Baml...

por Ernest, C. Steven, Chien, Jenny Y., Patel, Dipak R., Chigutsa, Emmanuel
Publicado 2022

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection

por Chigutsa, Emmanuel, O’Brien, Lisa, Ferguson‐Sells, Lisa, Long, Amanda, Chien, Jenny
Publicado 2021

Optimization of trial duration to predict long‐term HbA1c change with therapy: A pharmacometrics simulation‐based evaluation

por Kunina, Hanna, Al‐Mashat, Alex, Chien, Jenny Y., Garhyan, Parag, Kjellsson, Maria C.
Publicado 2022

A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clin...

por Chigutsa, Emmanuel, Jordie, Eric, Riggs, Matthew, Nirula, Ajay, Elmokadem, Ahmed, Knab, Tim, Chien, Jenny Y.
Publicado 2021

Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin

por Frias, Juan Pablo, Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Wullenweber, Paula, Haupt, Axel, Kazda, Christof
Publicado 2021

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

por Kazda, Christof M., Bue-Valleskey, Juliana M., Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Wullenweber, Paula, Haupt, Axel, Dahl, Dominik
Publicado 2023

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

por Bue-Valleskey, Juliana M., Kazda, Christof M., Ma, Chenchen, Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Haupt, Axel, Frias, Juan P.
Publicado 2023

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

por Upadhyaya, Himanshu P., Chien, Jenny Y., Long, Amanda J., Bohm, Martin S., Kallewaard, Nicole L., Macpherson, Lisa F., Patel, Dipak R., Hufford, Matthew M., Krull, Constance J., Ang, Jocelyn Y., Chen, Peter, Muller, William J., Potts, Jeffrey A., Quinn, Timothy, Williams, Mark
Publicado 2023

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

por Chen, Peter, Datta, Gourab, Grace Li, Ying, Chien, Jenny, Price, Karen, Chigutsa, Emmanuel, Brown‐Augsburger, Patricia, Poorbaugh, Josh, Fill, Jeffrey, Benschop, Robert J., Rouphael, Nadine, Kay, Ariel, Mulligan, Mark J., Saxena, Amit, Fischer, William A., Dougan, Michael, Klekotka, Paul, Nirula, Ajay, Benson, Charles
Publicado 2021